Hacı Can Direk
Hacı Can Direk has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Anil Erdik
Department of Urology, Karasu State Hospital, Sakarya, Turkiye
1 shared publication - Deniz Gul
Department of Urology, Sakarya Training and Research Hospital, Sakarya, Türkiye
1 shared publication - Haci Ibrahim Cimen
Department of Urology, Faculty of Medicine, Sakarya University, Sakarya, Turkey
1 shared publication - Osman Köse
Department of Urology, Faculty of Medicine, Sakarya University, Sakarya, Turkey
1 shared publication - Yavuz Tarik Atik
Department of Urology, Sakarya University Training and Research Hospital, Sakarya, Turkey
1 shared publication
Latest Publications
- Open Access
- 20 December 2025
- Published by Sakarya Tip Dergisi in Sakarya Medical Journal
- Vol. 15 (4) , 397-404
Combined Therapy Superior to Monotherapy in Overactive Bladder Patients with Pelvic Organ Prolapse: A Retrospective Comparative Study
Objective: To compare short-term outcomes of behavioral, anticholinergic, and combined therapies in overactive bladder (OAB) patients with pelvic organ prolapse (POP). Methods: This single-center retrospective study included 90 women with OAB and POP (POP-Q stage ≤2) categorized as: Group 1 (behavioral therapy; n=30), Group 2 (anticholinergic therapy; n=30), and Group 3 (combined therapy; n=30). Validated questionnaires (IIQ-7, UDI-6, OAB-V8, ICIQ-SF) were used to assess symptom severity and quality of life (QoL) pre- and post-treatment. Statistical analyses employed ANOVA and paired t-tests, with p<0.05 considered significant. Results: All groups showed significant improvement in all questionnaires post-treatment (p<0.05), except UDI-6 in Groups 1 and 2. Combined therapy (Group 3) achieved the greatest reductions in scores: ICIQ-SF: (Δ10.74), IIQ-7: (Δ4.57), OAB-V8: (Δ4.31). Behavioral therapy (Group 1) outperformed anticholinergic therapy alone (Group 2) in symptom reduction (IIQ-7: Δ4.69 vs. Δ2.55; OAB-V8: Δ2.83 vs. Δ3.62; both p<0.05). Daily pad usage differed significantly among groups (Group 1: 2.2±1.4; Group 2: 3.1±0.8; Group 3: 4.3±1.3; p<0.001). Conclusion: While all therapies improved OAB symptoms, combined behavioral-pharmacological therapy demonstrated superior efficacy in reducing symptom severity and enhancing QoL in patients with concomitant POP. Behavioral monotherapy may be more effective than anticholinergic alone, supporting multimodal approaches as first-line management.
- 20 December 2025
- Published by Sakarya Tip Dergisi in Sakarya Medical Journal
- Vol. 15 (4) , 397-404
Open AccessCombined Therapy Superior to Monotherapy in Overactive Bladder Patients with Pelvic Organ Prolapse: A Retrospective Comparative Study
Objective: To compare short-term outcomes of behavioral, anticholinergic, and combined therapies in overactive bladder (OAB) patients with pelvic organ prolapse (POP). Methods: This single-center retrospective study included 90 women with OAB and POP (POP-Q stage ≤2) categorized as: Group 1 (behavioral therapy; n=30), Group 2 (anticholinergic therapy; n=30), and Group 3 (combined therapy; n=30). Validated questionnaires (IIQ-7, UDI-6, OAB-V8, ICIQ-SF) were used to assess symptom severity and quality of life (QoL) pre- and post-treatment. Statistical analyses employed ANOVA and paired t-tests, with p<0.05 considered significant. Results: All groups showed significant improvement in all questionnaires post-treatment (p<0.05), except UDI-6 in Groups 1 and 2. Combined therapy (Group 3) achieved the greatest reductions in scores: ICIQ-SF: (Δ10.74), IIQ-7: (Δ4.57), OAB-V8: (Δ4.31). Behavioral therapy (Group 1) outperformed anticholinergic therapy alone (Group 2) in symptom reduction (IIQ-7: Δ4.69 vs. Δ2.55; OAB-V8: Δ2.83 vs. Δ3.62; both p<0.05). Daily pad usage differed significantly among groups (Group 1: 2.2±1.4; Group 2: 3.1±0.8; Group 3: 4.3±1.3; p<0.001). Conclusion: While all therapies improved OAB symptoms, combined behavioral-pharmacological therapy demonstrated superior efficacy in reducing symptom severity and enhancing QoL in patients with concomitant POP. Behavioral monotherapy may be more effective than anticholinergic alone, supporting multimodal approaches as first-line management.